EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)

Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis

Emil Tanghetti, Linda Stein Gold, Edward Lain, Abby Abby

Journal of Drugs in Dermatology · 2025

DOI: 10.36849/jdd.8720 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Drugs in Dermatology, 2025. Verfasst von Emil Tanghetti und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Clobetasol, Dermatologic Agents, Nicotinic Acids, Psoriasis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClobetasolDermatologic AgentsNicotinic AcidsPsoriasisAdultAgedFemaleHumansMaleMiddle AgedAdministration, CutaneousDouble-Blind MethodDrug CombinationsFollow-Up StudiesSeverity of Illness IndexSkin CreamTreatment OutcomeRetinoids

Substanzen

ClobetasolDermatologic AgentsDrug CombinationsNicotinic AcidshalobetasoltazaroteneRetinoids

Zitieren

APA

Tanghetti, E., Stein Gold, L., Lain, E., & Abby, A. (2025). Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.8720

Vancouver

Tanghetti E, Stein Gold L, Lain E, Abby A. Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis. Journal of Drugs in Dermatology. 2025. doi:10.36849/jdd.8720

BibTeX
@article{Tanghetti2025,
  author = {Tanghetti, Emil and Stein Gold, Linda and Lain, Edward and Abby, Abby},
  title = {Clinical Profile of Halobetasol Propionate 0.01%/ Tazarotene 0.045% Lotion in Patients With Hyperkeratotic Plaque Psoriasis},
  journal = {Journal of Drugs in Dermatology},
  year = {2025},
  doi = {10.36849/jdd.8720}
}
Kostenlos starten →